| Heart disease and stroke statistics—2017 update: a report from the American Heart Association EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ... circulation 135 (10), e146-e603, 2017 | 26498 | 2017 |
| Heart disease and stroke statistics—2014 update: a report from the American Heart Association AS Go, D Mozaffarian, VL Roger, EJ Benjamin, JD Berry, MJ Blaha, S Dai, ... circulation 129 (3), e28-e292, 2014 | 17011 | 2014 |
| 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on … RA Nishimura, CM Otto, RO Bonow, BA Carabello, JP Erwin, RA Guyton, ... Journal of the American College of Cardiology 63 (22), e57-e185, 2014 | 9730* | 2014 |
| 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of … F Mach, C Baigent, AL Catapano, KC Koskinas, M Casula, L Badimon, ... European heart journal 41 (1), 111-188, 2020 | 9585 | 2020 |
| 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines DC Goff Jr, DM Lloyd-Jones, G Bennett, S Coady, RB D’agostino, ... Circulation 129 (25_suppl_2), S49-S73, 2014 | 7387 | 2014 |
| Dapagliflozin in patients with heart failure and reduced ejection fraction JJV McMurray, SD Solomon, SE Inzucchi, L Køber, MN Kosiborod, ... New England Journal of Medicine 381 (21), 1995-2008, 2019 | 6566 | 2019 |
| 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association … EA Amsterdam, NK Wenger, RG Brindis, DE Casey, TG Ganiats, ... Journal of the American college of cardiology 64 (24), e139-e228, 2014 | 6544* | 2014 |
| Dapagliflozin and cardiovascular outcomes in type 2 diabetes SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... New England Journal of Medicine 380 (4), 347-357, 2019 | 6420 | 2019 |
| Evolocumab and clinical outcomes in patients with cardiovascular disease MS Sabatine, RP Giugliano, AC Keech, N Honarpour, SD Wiviott, ... New England journal of medicine 376 (18), 1713-1722, 2017 | 6128 | 2017 |
| Cytochrome p-450 polymorphisms and response to clopidogrel JL Mega, SL Close, SD Wiviott, L Shen, RD Hockett, JT Brandt, JR Walker, ... New England journal of medicine 360 (4), 354-362, 2009 | 3201 | 2009 |
| 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American … GN Levine, ER Bates, JA Bittl, RG Brindis, SD Fihn, LA Fleisher, ... Circulation 134 (10), e123-e155, 2016 | 3030 | 2016 |
| Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation MS Sabatine, CP Cannon, CM Gibson, JL López-Sendón, G Montalescot, ... New England Journal of Medicine 352 (12), 1179-1189, 2005 | 2947 | 2005 |
| SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome … TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich, MP Bonaca, ... The Lancet 393 (10166), 31-39, 2019 | 2805 | 2019 |
| Long-term use of ticagrelor in patients with prior myocardial infarction MP Bonaca, DL Bhatt, M Cohen, PG Steg, RF Storey, EC Jensen, ... New England Journal of Medicine 372 (19), 1791-1800, 2015 | 2247 | 2015 |
| The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes JA De Lemos, DA Morrow, JH Bentley, T Omland, MS Sabatine, ... New England Journal of Medicine 345 (14), 1014-1021, 2001 | 2127 | 2001 |
| Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis D Preiss, SRK Seshasai, P Welsh, SA Murphy, JE Ho, DD Waters, ... Jama 305 (24), 2556-2564, 2011 | 1943 | 2011 |
| Efficacy and safety of evolocumab in reducing lipids and cardiovascular events MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, DJ Blom, J Robinson, ... New England Journal of Medicine 372 (16), 1500-1509, 2015 | 1747 | 2015 |
| Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis MG Silverman, BA Ference, K Im, SD Wiviott, RP Giugliano, SM Grundy, ... Jama 316 (12), 1289-1297, 2016 | 1507 | 2016 |
| Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JL Mega, T Simon, JP Collet, JL Anderson, EM Antman, K Bliden, ... Jama 304 (16), 1821-1830, 2010 | 1441 | 2010 |
| Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in … MS Sabatine, DA Morrow, KA Jablonski, MM Rice, JW Warnica, ... Circulation 115 (12), 1528-1536, 2007 | 1181* | 2007 |
